Latest news with #EAP
Business Wire
4 days ago
- Business
- Business Wire
Names Tricon Residential One of the Best Workplaces in Real Estate for 2025
TORONTO--(BUSINESS WIRE)--Tricon Residential Inc., a Blackstone Real Estate portfolio company, has been named one of the 2025 Best Workplaces in Real Estate™ by Great Place To Work ®. This marks Tricon's fifth year on the list and reflects the Company's continued investment in building a positive workplace culture focused on delivering high-quality service to residents across North America. 'At Tricon, our people-first approach starts with our employees,' said Gary Berman, President and CEO of Tricon Residential. 'To deliver a high standard of care for our residents, we focus on building a culture where our teams feel supported, valued, and aligned with a clear purpose. This recognition from Great Place To Work affirms that when employees are set up to succeed, they deliver meaningful impact far beyond the workplace, including in the homes and communities we serve.' In survey responses to Great Place To Work, 87% of Tricon Residential employees say Tricon fosters a positive work environment, consistently citing the Company's strong sense of purpose, investment in employee well-being and active community involvement as pivotal factors. 'Our job is to make sure residents feel heard, valued, and cared for—and that's only possible because of the culture Tricon has built,' said Marc Leclerc, Resident Satisfaction Manager. 'Through investment in our well-being, training, and success, we have the support we need to make a real difference in residents' lives.' Putting Employee Well-Being First Tricon offers a range of health and wellness programs and benefits designed to support employees' physical, social, emotional and financial needs. Key highlights of Tricon's employee well-being initiatives include: Comprehensive Wellness Platform: Provides a wide range of services, including virtual mental health treatment options, offered at no cost. Flex Work Hours and Competitive Wages: Offers flexible work hours, remote work options to accommodate diverse schedules, and competitive wages for employees in every market. Annual Fitness Benefits: Supports employees' physical well-being with access to employer-funded fitness benefits. Employee Assistance Program (EAP): Ensures that employees have access to resources and confidential counseling services, offered at no cost. Investing in Communities Through Employee Action Tricon actively encourages and supports its employees in giving back to the communities in which it operates. Every team member receives: Eight hours of paid volunteer time per year $100 to donate to a cause of their choice, with Tricon matching all contributions Since the launch of these programs, Tricon employees have donated more than $267,000. In 2024 alone, employees volunteered over 10,000 hours in support of local food banks, education initiatives, youth programs, and more. Recognized for Impact In addition to the 2025 recognition from Great Place To Work, Tricon was named a Top 100 Inspiring Workplace in North America by the Inspiring Workplaces Group in 2024, and a Best Workplace in Real Estate & Property Development in 2022. The Best Workplaces in Real Estate award is highly competitive. Great Place To Work ®, the global authority on workplace culture, determines its lists using a unique methodology to evaluate and certify thousands of organizations in America's largest ongoing annual workforce study, based on over 1.3 million survey responses and data from companies representing more than 8.2 million employees in 2024 alone. Survey responses reflect a comprehensive picture of the workplace experience. "Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience," said Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of employees regarding their company culture. 'By successfully earning this recognition, it is evident that Tricon Residential stands out as one of the top companies to work for, providing a great workplace environment for its employees." About Tricon Residential Inc. Tricon Residential is an owner, operator and developer of single-family rental homes in the U.S. and multi-family apartments in Canada. Our commitment to enriching the lives of our employees, residents and local communities underpins Tricon's culture and business philosophy. We provide high-quality rental housing options for families across the United States and Canada through our technology-enabled operating platform and dedicated on-the-ground operating teams. Our development programs are also delivering thousands of new rental homes and apartments as part of our commitment to help solve the housing supply shortage. At Tricon, we imagine a world where housing unlocks life's potential. For more information, visit About Great Place to Work Certification™ Great Place To Work® Certification™ is the most definitive 'employer-of-choice' recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place To Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified. As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.
Yahoo
13-06-2025
- Health
- Yahoo
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg® Independent dataset from EAP reinforces the findings from the pivotal ARES trial and has also been included in the EMA Marketing Authorization Application submitted on June 2nd, 2025 EAP for Xervyteg® in aGvHD is currently running in 11 countries* providing expanded access to patients with high unmet medical needs LYON, France, June 13, 2025--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that Professor Mohamad Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University, will present updated data for Xervyteg® (MaaT013) in treating acute Graft-versus-Host Disease (aGvHD) under the Early Access Program (EAP) at the European Hematology Association (EHA) Annual Congress 2025. This independent EAP dataset further supports the efficacy and safety profile of Xervyteg® previously shown in the pivotal ARES trial. It also confirms the breakthrough potential of Xervyteg® for aGvHD patients with limited treatment options and it also serves as supportive data within the Marketing Authorization Application (MAA) recently submitted to the European Medicines Agency (EMA). Key highlights: aGvHD is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. The patients (N=173) treated in EAP previously failed 1 to 6 aGvHD systemic treatment lines and most had grade III (49%) or IV (38%) aGvHD. The real-world data presented underscores the favorable safety profile of Xervyteg® the strong and durable responses, translating into increased overall survival: Gastrointestinal Overall Response Rate (GI-ORR) of 53% at D28, with Complete Response (CR) observed in 30% of patients; all-organ Overall Response Rate (ORR) was 50% with 26% CR. Response is maintained at D56 indicating a long-term disease control with a GI-ORR of 47% and an ORR considering all organs of 46%. Overall Survival (OS) in all patients was 55% at 6 months, 48% at 12 months, 44% at 24 months. Xervyteg® displayed a good overall safety profile in the EAP population. OS was significantly higher in patients who responded to Xervyteg® (MaaT013) compared to non-responders (69% versus 25% at 12 months, and 61% versus 25% at 24 months). Median survival in all patients was 312 days. In responder patients, median survival was 834 days vs 69 days in non-responders. A subset of patients (n=70) failing both steroid resistant (SR) and ruxolitinib resistant (RR) and thus resembling the cohort enrolled in the pivotal Phase 3 ARES trial (NCT04769895), exhibited a significant and consistent efficacy profile: At both Day 28 and Day 56, Xervyteg® demonstrated durable efficacy in SR/RR aGvHD patients, with GI-ORRs of 57% and Complete Response (CR) observed in 44% of patients at D28 and 51% at D56. All-organs ORR was 54% with 41% CR at D28, and 55% with 48% CR at D56. OS was 55% at 6 months, 51% at 12 months, 40% at 24 months. OS was significantly higher in patients who responded to Xervyteg® compared to non-responders (77% versus 14% at 12 months, and 59% versus 14% at 24 months). Median survival in all 70 patients was 445 days. In responder patients, median survival was 834 days vs 53 days in non-responders. The complete data may be found here. "The consistency between the real-world Early Access Program data and our pivotal ARES trial underscores Xervyteg®'s clinical benefit for patients with severe, treatment-resistant aGvHD," said Dr. Gianfranco Pittari, PhD, Chief Medical Officer at MaaT Pharma. "This is particularly meaningful for clinicians and patients, as it confirms the potential of microbiome therapies to deliver long-term survival benefits in a population with historically poor outcomes." In comparison, historical data from Abedin et al. 2021 demonstrated that in a similar population of patients, i.e. third-line aGvHD patients receiving additional treatment after ruxolitinib failure, the median survival was only 28 days. "Among patients who responded by Day 28, the majority achieved a complete resolution of aGvHD symptoms — a strong predictor of sustained disease control over time. The overall safety profile is favorable in this high-risk patient population," outlines Professor Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University. Details of the Oral Presentation: Title: Pooled Fecal Allogeneic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in Europe Abstract number: S260 Presenting Author: Mohamad Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University Session title: s424 Stem cell transplantation - Session 2 Date & Time: 13/06/2025 (17:00 - 17:15 CEST) - Brown Hall 3 MaaT Pharma also presented a poster on the design of its ongoing Phase 2b trial (PHOEBUS) evaluating MaaT033 to enhance overall survival in allo-HSCT. This international, multi-center trial (NCT05762211) is the largest randomized controlled study to date of a microbiome-based therapy in oncology, enrolling up to 387 patients across 60 sites. --- About MaaT PharmaMaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking StatementsAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim", "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. * France, Austria, Belgium, Canada, Germany, Italy, Lebanon, Spain, Sweden, Switzerland & USA View source version on Contacts MaaT Pharma – Investor RelationsGuilhaume DEBROAS, of Investor Relations+33 6 16 48 92 50invest@ Rx Communications Group – U.S. Investor RelationsMichael MillerManaging Director+1-917-633-6086mmiller@ MaaT Pharma – Media RelationsPauline RICHAUDSenior PR & Corporate Communications Manager+33 6 14 06 45 92media@ Catalytic Agency – U.S. Media RelationsHeather SheaMedia relations for MaaT Pharma+1 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
13-06-2025
- Health
- Business Wire
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg ® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
LYON, France--(BUSINESS WIRE)--Regulatory News: 'The consistency between the real-world Early Access Program data and our pivotal ARES trial underscores Xervyteg®'s clinical benefit for patients with severe, treatment-resistant aGvHD,' said Dr. Gianfranco Pittari, Chief Medical Officer at MaaT Pharma. MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that Professor Mohamad Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University, will present updated data for Xervyteg ® (MaaT013) in treating acute Graft-versus-Host Disease (aGvHD) under the Early Access Program (EAP) at the European Hematology Association (EHA) Annual Congress 2025. This independent EAP dataset further supports the efficacy and safety profile of Xervyteg ® previously shown in the pivotal ARES trial. It also confirms the breakthrough potential of Xervyteg ® for aGvHD patients with limited treatment options and it also serves as supportive data within the Marketing Authorization Application (MAA) recently submitted to the European Medicines Agency (EMA). Key highlights: aGvHD is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. The patients (N=173) treated in EAP previously failed 1 to 6 aGvHD systemic treatment lines and most had grade III (49%) or IV (38%) aGvHD. The real-world data presented underscores the favorable safety profile of Xervyteg ® the strong and durable responses, translating into increased overall survival: Gastrointestinal Overall Response Rate (GI-ORR) of 53% at D28, with Complete Response (CR) observed in 30% of patients; all-organ Overall Response Rate (ORR) was 50% with 26% CR. Response is maintained at D56 indicating a long-term disease control with a GI-ORR of 47% and an ORR considering all organs of 46%. Overall Survival (OS) in all patients was 55% at 6 months, 48% at 12 months, 44% at 24 months. Xervyteg ® displayed a good overall safety profile in the EAP population. OS was significantly higher in patients who responded to Xervyteg ® (MaaT013) compared to non-responders (69% versus 25% at 12 months, and 61% versus 25% at 24 months). Median survival in all patients was 312 days. In responder patients, median survival was 834 days vs 69 days in non-responders. A subset of patients (n=70) failing both steroid resistant (SR) and ruxolitinib resistant (RR) and thus resembling the cohort enrolled in the pivotal Phase 3 ARES trial (NCT04769895), exhibited a significant and consistent efficacy profile: At both Day 28 and Day 56, Xervyteg ® demonstrated durable efficacy in SR/RR aGvHD patients, with GI-ORRs of 57% and Complete Response (CR) observed in 44% of patients at D28 and 51% at D56. All-organs ORR was 54% with 41% CR at D28, and 55% with 48% CR at D56. OS was 55% at 6 months, 51% at 12 months, 40% at 24 months. OS was significantly higher in patients who responded to Xervyteg ® compared to non-responders (77% versus 14% at 12 months, and 59% versus 14% at 24 months). Median survival in all 70 patients was 445 days. In responder patients, median survival was 834 days vs 53 days in non-responders. The complete data may be found here. 'The consistency between the real-world Early Access Program data and our pivotal ARES trial underscores Xervyteg ® 's clinical benefit for patients with severe, treatment-resistant aGvHD,' said Dr. Gianfranco Pittari, PhD, Chief Medical Officer at MaaT Pharma. 'This is particularly meaningful for clinicians and patients, as it confirms the potential of microbiome therapies to deliver long-term survival benefits in a population with historically poor outcomes.' In comparison, historical data from Abedin et al. 2021 demonstrated that in a similar population of patients, i.e. third-line aGvHD patients receiving additional treatment after ruxolitinib failure, the median survival was only 28 days. 'Among patients who responded by Day 28, the majority achieved a complete resolution of aGvHD symptoms — a strong predictor of sustained disease control over time. The overall safety profile is favorable in this high-risk patient population,' outlines Professor Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University. Details of the Oral Presentation: Title: Pooled Fecal Allogeneic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in Europe Abstract number: S260 Presenting Author: Mohamad Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University Session title: s424 Stem cell transplantation - Session 2 Date & Time: 13/06/2025 (17:00 - 17:15 CEST) - Brown Hall 3 MaaT Pharma also presented a poster on the design of its ongoing Phase 2b trial (PHOEBUS) evaluating MaaT033 to enhance overall survival in allo-HSCT. This international, multi-center trial (NCT05762211) is the largest randomized controlled study to date of a microbiome-based therapy in oncology, enrolling up to 387 patients across 60 sites. --- About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. * France, Austria, Belgium, Canada, Germany, Italy, Lebanon, Spain, Sweden, Switzerland & USA
Business Standard
12-06-2025
- Business
- Business Standard
Colliers releases 2024 Global Sustainability Report; announces refreshed sustainability strategy, 'Built to Last'
PRNewswire Bangalore (Karnataka) [India], June 12: Colliers (NASDAQ: CIGI), (TSX: CIGI), a leading diversified real estate professional services firm, released its 2024 Global Sustainability Report, highlighting the firm's achievements and progress against targets established in 2021. The company's refreshed sustainability strategy, Built to Last, elaborately conveyed through the report, includes targets for addressing the firm's own GHG emissions and helping its clients do the same. The strategic framework rests on three interconnecting themes - Environmental Sustainability, Workplace Experience, and Ethical Governance & Practices. Environmental Sustainability addresses the growing need for decarbonization pathways that enhance asset resilience and align with climate change mitigation goals. Workplace Experience focuses on people - their safety, well-being, and acceptance. And Ethical Governance & Practices emphasizes the firm's commitment to ethical business conduct and transparent governance, particularly around data privacy and proactive cybersecurity measures to protect the interests of internal and external stakeholders. Inclusiveness and instilling a sense of belonging among its people remain a key area of focus for the firm. Several of the firm's Asia Pacific markets including India strengthened their Employee Assistance Programme (EAP) offering to make services, personalized support and wellness workshops more accessible to employees. Further, the enhanced employee referral program has broadened the hiring pool by leveraging employees' social networks. Asia Pacific highlights in the report include: * 39.6% reduction in Scope 1 and 2 emissions per square foot from a 2021 baseline * Secured WELL Health-Safety Ratings in all Colliers offices in Asia Pacific * 108% participation in Colliers Gives global volunteering program * Approx 90% engagement in our global employee survey, with engagement scores exceeding external benchmarks * 30% of manager+ roles held by women "At Colliers, sustainability is not just a commitment but the foundation of our future. With our refreshed sustainability strategy, 'Built to Last', we are prioritizing people, governance, and environmental sustainability, ensuring that progress is both impactful and enduring. From sustainable asset investing to integrating new ESG-focused services, we are embedding sustainability into every facet of our business. Our unbiased hiring practices, increased women leadership, and sensitivity trainings reflect our dedication to inclusiveness, while our community initiatives reinforce our responsibility to giving back. Winning key accolades and acquiring certifications like Great Place to Work is a testament to our ethical stance and steadfast pursuit of excellence and sustainable growth. As we move forward, we will continue leading with integrity, innovation, and a deep-rooted commitment to doing right by our people, clients and communities," says Sankey Prasad, Chairman & MD, Middle-East & India, Colliers. "Our latest global sustainability report underscores our unwavering commitment to our ESG goals - prioritizing people, governance, and environmental sustainability. By integrating compliant strategies, sustainable asset investments, and inclusive leadership practices, we continue to drive meaningful change. As we embrace technological advancements, we are committed to harnessing AI and pioneering technologies responsibly, integrating policies that drive ethical innovation, improved efficiency, and ascending growth. Our refreshed approach is also deeply rooted in fostering an inclusive, transparent, and forward-thinking organization. We prioritize the physical and mental well-being of our employees, creating a supportive culture where they can thrive. We hope to empower professionals from diverse backgrounds, ensuring that all our people have equal access to opportunity and resources that unlock their full potential," says Badal Yagnik, Chief Executive Officer, Colliers India. The full 2024 Global Sustainability Report is available at About Colliers Colliers (NASDAQ: CIGI) (TSX: CIGI) is a global diversified professional services and investment management company. Operating through three industry-leading platforms - Real Estate Services, Engineering, and Investment Management - we have a proven business model, an enterprising culture, and a unique partnership philosophy that drives growth and value creation. For 30 years, Colliers has consistently delivered approximately 20% compound annual returns for shareholders, fueled by visionary leadership, significant inside ownership and substantial recurring earnings. With nearly $5.0 billion in annual revenues, a team of 23,000 professionals, and more than $100 billion in assets under management, Colliers remains committed to accelerating the success of our clients, investors, and people worldwide. Learn more at X @Colliers or LinkedIn.
The Star
11-06-2025
- Business
- The Star
World Bank revises Malaysia's 2025 GDP growth forecast to 3.9%
KUALA LUMPUR: Malaysia's gross domestic product (GDP) growth forecast for 2025 has been revised to 3.9 per cent, a 0.6 percentage-point downgrade from January 2025's projection, according to the World Bank's Global Economic Prospects report. The downgrade was attributed to the unpredictable macroeconomic effects of higher trade barriers, which the World Bank said could weigh on growth despite having benefited from fiscal policy support such as social spending programmes and public investment. It also stated that modest fiscal consolidation is expected to continue in Malaysia. Besides Malaysia, other East Asia and Pacific (EAP) countries also saw notable revisions, with the Philippines and Vietnam each experiencing a 0.8 percentage-point downgrade, with growth forecasts lowered to 5.3 per cent and 5.8 per cent, respectively. Thailand's projection was cut by 1.1 percentage points to 1.8 per cent, while Myanmar recorded the sharpest downgrade of 4.5 percentage points, bringing its 2025 GDP forecast to -2.5 per cent, said the report. Global growth is projected to decline to 2.3 per cent in 2025, with a slowdown in most economies compared to last year. This rate of growth will be the slowest since 2008, excluding periods of global recession. According to the report, Malaysia, which is among the economies with large export-oriented manufacturing sectors, is particularly exposed to a reemergence of trade tensions, higher trade costs, and weaker growth in major economies. It said gauges of manufacturing activity, including headline manufacturing Purchasing Managers' Indexes (PMIs) and goods trade indicators, have eased recently. Some trade-exposed emerging market and developing economies (EMDEs), such as Malaysia, have seen the new export orders component of the manufacturing PMI weaken markedly since November amid increasing global trade policy uncertainty, the report said. - Bernama
